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Abstract: Comorbidities in patients with rheumatoid arthritis (RA) are often associated with poor
health outcomes and increased mortality. Treatment decisions should take into account these comor-
bidities due to known or suspected associations with certain drug classes. In clinical practice, it is
critical to balance potential treatment benefit against the possible risks for comorbidities as well as the
articular manifestations of RA. This review summarises the current literature relating to prevalence
and risk factors for the important comorbidities of cardiovascular disease, infections, lymphomas and
nonmelanoma skin cancers in patients with RA. The impact on patient outcomes and the interplay
between these comorbidities and the therapeutic options currently available, including tumour
necrosis factor inhibitors and newer biological therapies, are also explored. As newer RA therapies
are developed, and patients gain wider and earlier access to advanced therapies, in part due to the
emergence of biosimilars, it is important to consider the prevention or treatment of comorbidities as
part of the overall management of RA.
Keywords: rheumatoid arthritis; comorbidities; extra-articular manifestations; tumour necrosis
factor; cardiovascular disease; infections; lymphoma; nonmelanoma skin cancers
1. Introduction
The relationship between rheumatoid arthritis (RA) and a wide range of comorbid
conditions and extra-articular manifestations is well known [1–3]. The development of co-
morbidities is associated with poor health outcomes, including decreased function, reduced
quality of life, and increased morbidity and mortality [1,2,4]. The identification of tumour
necrosis factor (TNF) as a therapeutic target and its subsequent validation in clinical trials
led to the approval of biologic TNF inhibitors for the treatment of RA over two decades ago,
greatly improving the outlook for many patients [5–7]. The success of this therapeutic class
was followed by the introduction of other biologic disease-modifying antirheumatic drugs
(bDMARDs) and, more recently, small molecule targeted synthetic disease-modifying
antirheumatic drugs (tsDMARDs) [7]. However, high costs of originator drugs have re-
sulted in varying degrees of access restrictions across national health care economies [7,8].
Furthermore, although all targeted therapies have a broadly similar efficacy, they differ in
mechanisms of action and associated target-related benefits and toxicities [9]. In the face of
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a wide range of available contemporary treatment options and management strategies for
RA [10,11], careful consideration needs to be given to certain comorbidities with respect
to treatment decisions [10–12]. The large international population-based, cross-sectional
COMOrbidities in Rheumatoid Arthritis (COMORA) study evaluated the prevalence of
comorbidities in 3920 patients with RA from 17 countries [1]. The most commonly observed
comorbidities (past or current) were depression (15%), asthma (7%), cardiovascular (CV)
events (myocardial infarction (MI), stroke; 6%), solid-organ malignancies (5%), and chronic
obstructive pulmonary disease (4%) [1]. Results from the COMORA study demonstrated
considerable intercountry variability for the prevalence of these comorbidities; for example,
the prevalence of depression was 2% in Morocco compared with 33% in the USA [1]. For
patients with RA, cardiovascular disease (CVD), infections and malignancies are important
comorbidities as they may lead to an increased risk of mortality [1]. Furthermore, they are
also impacted by at least one of the therapeutic options currently available for the treatment
of RA [13–15] and may therefore affect treatment decisions in clinical practice. Notably, pa-
tients with congestive heart failure, active hepatitis B, or a history of other serious infections
or malignancy are classified as high risk in the current American College of Rheumatology
treatment guidelines for RA, and they have separate treatment recommendations [10].
In this review, the current literature is discussed with respect to the prevalence and risk
factors for CVD, infections and selected malignancies (lymphoma and nonmelanoma skin
cancers (NMSC)—basal cell carcinoma (BCC) and squamous cell carcinoma (SCC)). The
impact on patient management and outcomes and associations with treatments employed
in clinical practice is also explored. Although this review is not limited to TNF inhibitors,
they are the focus of much of the discussion due to the availability of data. Moreover,
due to the extensive clinical experience with these agents and the more recent impact of
biosimilars on cost, they are expected to retain a major role in the treatment of RA in the
foreseeable future [16,17].
2. Search Strategy
A narrative literature search was conducted on 8 September 2020 to address research
questions related to the dominant comorbidities of CVD, infections, lymphoma and NMSC
in patients with RA. For each of these comorbidities, the literature search aimed to identify
publications relating to their prevalence and associated risk factors, their impact on clinical
outcomes, health-related quality of life and patient management, and the effects of TNF
inhibitors on these comorbidities.
The PubMed database was searched using a keyword search restricted to “Title Only”
using terms relating to RA and cardiovascular (CV), infection, lymphoma, BCC or SCC.
Search results were further refined by limiting the search using a MeSH Major Topic or
keyword title search using search terms to identify publications discussing the prevalence
of comorbidities, the factors contributing to comorbidities, the impact of comorbidities and
the effect of TNF inhibitors on comorbidities. The complete search strings are provided in
Table S1 in the supplementary materials. Only articles published within the past 5 years
were included. Articles were reviewed for relevance based on the article title and abstract,
with all article types taken into consideration if they included data relevant to the research
questions.
To provide essential historical context to the current literature, several sections include
references published before 2015. Additional references were identified through searching
the bibliographies of retrieved articles, through a search of abstracts presented at the
European League Against Rheumatism (EULAR) congress in 2019 and 2020, and through
author suggestions.
3. CV Comorbidities in RA
3.1. Prevalence of CVD in Patients with RA
CVD is a major comorbidity affecting patients with RA and a leading cause of mor-
bidity and mortality in this population [18]. Multiple recent studies have highlighted the
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extent to which patients with RA are affected by CVD, although comparisons between
studies are often hindered by differences in the definition of events (Table 1). Patients with
RA have been shown to be at higher risk of CVD compared with healthy controls. Using
a large database of primary care patients across England, patients with early RA had a
33% higher CVD risk (composite endpoint of MI, stroke or heart failure) than matched
controls without RA after adjustment for baseline differences including inflammatory
markers, seropositivity and use of glucocorticoids (GCs) at diagnosis [19]. Similarly, in
the CARdiovascular research and RhEumatoid arthritis (CARRÉ) long-term, prospective
cohort study, patients with RA had a risk of CV events (coronary heart disease, cerebral
arterial disease or peripheral arterial disease) that was almost double that of the general
population. In the same study, the increased risk of CVD associated with RA was even
higher than that associated with diabetes mellitus [20]. An increased risk of heart failure in
patients with RA has also been highlighted recently in a systematic review that included
over 5 million patients; in this study, the incidence of heart failure was almost two-fold
higher in patients with RA than in matched controls [21]. It is important to note that the
increased risk of CVD associated with RA may already be present at an early stage of the
disease, with an excess of stroke and heart failure reported prior to RA diagnosis compared
with matched controls in England [19].
Table 1. Prevalence of cardiovascular disease in patients with rheumatoid arthritis.
Citation Country Study Type Patients (n) CV Event Prevalence (%)















Crowson 2017 [24] International Prospective, cohort 5638 CVD events * Men: 20.9%
†
Women: 11.1% †
















4586 MI or stroke 6.0%
Gomes 2017 [26] Brazil Cross-sectional,population-based 296 MI 4.4%















Agca 2020 [20] Netherlands
Prospective cohort
CARRÉ
326 CV event ‖
32 per 1000
person-years ¶
Solomon 2015 [28] USA RegistryCORRONA US 24,989




* ACS including MI, stable or unstable angina, revascularisation, CV deaths, cerebrovascular events, peripheral vascular events. † Unad-
justed cumulative incidence at 10 years after baseline. ‡ Including congestive heart failure, coronary artery disease, MI, unstable angina,
peripheral arterial disease, stroke, transient ischaemic attack and other. § Defined as MI, transient or permanent cerebrovascular event,
or CV-associated death. ¶ Unadjusted incidence rate. ‖ Defined as a verified medical history of coronary heart disease, cerebral arterial
disease or peripheral arterial disease. Abbreviations: ACS, acute coronary syndrome; CARRÉ, CARdiovascular research and RhEumatoid
arthritis; COMORA, COMOrbidities in Rheumatoid Arthritis; CORRONA, Consortium of Rheumatology Researchers of North America;
CV, cardiovascular; CVD, cardiovascular disease; MACE, major adverse CV event; MI, myocardial infarction.
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Imaging studies have also demonstrated the increased risk of CV in patients with
RA. A study of patients referred for computed tomography angiography due to chest
pain reported a higher prevalence of coronary artery calcification in RA patients than in
controls [29]. The strongest associations were reported in seropositive RA patients and in
patients requiring treatment with GCs for relapse or flare; treatment with conventional
synthetic disease-modifying antirheumatic drugs (csDMARDs), but not bDMARDs, was
also associated with a tendency for increased risk of obstructive coronary artery disease
(CAD). Consistent with these findings, a recent meta-analysis of computed tomography
(CT) studies reported that asymptomatic CAD is more prevalent in patients with RA than
in controls [30]. Although the evidence was limited, it was also noted that patients with
RA had a higher prevalence of moderate-to-severe CAD and more multivessel CAD [30].
CV abnormalities in patients without overt cardiac disease have also been detected by
echocardiography in patients with RA. In a prospective study in Italy, a five-fold increased
risk of abnormal changes to the structure and function of the left ventricle was observed in
patients with RA compared with matched controls [31]. In this study, left ventricular strain
was independently associated with a 2.4-fold increased risk of all-cause hospitalisation and
a 6.6-fold increased risk of CV-related hospitalisation.
3.2. Impact of CV Comorbidities in Patients with RA
Patients with comorbid CVD and RA tend to have worse long-term health outcomes
than patients with CVD alone. In a large population cohort study in Denmark of patients
undergoing coronary angiography, the 10-year risk of MI was higher in patients with RA
and coincident CAD compared with non-RA patients with CAD (12.2% vs. 9.9%). Similar
associations were observed for major adverse CV events (MACE) and all-cause mortal-
ity [32]. Worse outcomes were also noted in a recent meta-analysis, which demonstrated
that patients with co-existing CAD and RA had significantly increased risks of all-cause
mortality, cardiac death and congestive heart failure compared with CAD patients without
RA. In patients who underwent percutaneous coronary intervention, all-cause mortality
rates remained significantly higher in patients with RA and CAD than in non-RA patients
with CAD [33]. Similarly, in a large cohort study of patients who experienced an acute coro-
nary syndrome (ACS) event, patients with RA had a 27% and 50% increased risk of ACS
recurrence or mortality, respectively, after a mean 2-year follow-up compared with controls,
which remained statistically significant even after adjustment for baseline comorbidities.
This increased risk could not be explained by differences in the use of standard-of-care
secondary preventative drugs [34].
The presence of RA can also have a negative impact on short-term outcomes following
CV events. In a recent database study in Taiwan, patients with RA had a higher risk of in-
hospital mortality after acute MI, intracranial haemorrhage or ischaemic stroke compared
with patients without RA [35]. Similarly, a large Swedish study demonstrated that mortality
rates within 1 week and 1 month following an ACS event were significantly higher in
patients with RA compared with a matched cohort from the general population, even after
adjustment for age, sex, pre-existing comorbidities and pharmacotherapies, and ACS type.
Patients with RA also had higher troponin levels, and higher frequencies of in-hospital
complications and ST-segment elevation MIs compared with the control cohort [36]. In
contrast, a small study in Israel found that the outcome and prognosis of patients with
ACS were not affected by the coexistence of inflammatory rheumatic diseases. The authors
of this study argued that excess mortality in patients with rheumatic diseases reflects
the higher prevalence of CVD in this population rather than worse outcomes for CV
events [37]. However, it should be noted that this study included only 20 patients with
ACS and inflammatory rheumatic conditions, of whom only 11 had RA.
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3.3. Risk Factors for CVD in Patients with RA
The increased CVD risk observed in patients with RA is likely to be multifactorial,
reflecting an increased prevalence of traditional CVD risk factors, the impact of systemic
inflammation and potential side effects from medications used to treat RA.
The burden of traditional risk factors for CVD among patients with RA has been
extensively documented, with multiple large studies reporting a high prevalence of current
tobacco use (ranging from 19 to 29%), hypertension (19 to 61%), diabetes mellitus (5 to
14%) and hyperlipidaemia (10 to 32%) [1,3,19,20,24,28]. In addition, many patients were
reported to be overweight or obese (mean body mass index (BMI) ranged from 27 to
29 kg/m2) [19,20,24,38]. In the COMORA study, around half of the enrolled patients were
overweight or obese (51%), and almost half (43%) were considered to have a high 10-year
risk of CVD based on the Framingham score [1]. Compared with the general population,
the prevalence of traditional CVD risk factors is often higher amongst patients with RA.
For example, in a large study of primary care patients in England, patients with RA had
a higher BMI and were significantly more likely to have diabetes and to be current or
former smokers than age- and gender-matched controls without RA [19]. A similar pattern
was reported in the CARRÉ study, with patients with RA having a significantly higher
prevalence of hypertension and tobacco use than a control population [20]. Interestingly,
in both studies, total and low-density lipoprotein (LDL) cholesterol levels were lower in
patients with RA than in controls [19,20].
To date, numerous studies have shown that traditional risk factors contribute to
the increased CVD risk faced by patients with RA. In a large, international cohort study,
traditional risk factors were responsible for 49% of the CV risk in RA patients, with
current smoking status and hypertension being major modifiable risk factors [24]. Similar
conclusions were drawn by Nikiphorou et al., who reported that current smoking, BMI
and diabetes were associated with a higher rate of CVD among patients with RA [19]. At a
subclinical level, traditional risk factors (age, mean arterial pressure and diabetes) have
also been shown to be independently associated with worsening atherosclerosis in patients
with RA who had not experienced previous CV events [39].
The presence of traditional risk factors does not fully account for the increased CVD
risk in patients with RA, with many studies reporting that a considerable residual risk
remains even after adjustment for traditional risk factors [19,20,24]. Systemic inflammation
may, at least in part, explain the remaining risk, and this theory is supported by a multitude
of studies demonstrating an association between high RA disease activity and increased
CVD risk (Table 2) [24,28,39–44]. The relationship between chronic inflammation and
CVD remains to be fully delineated, but it has been reported that the proinflammatory
mechanisms underlying the pathogenesis of RA may contribute to the development of
atherosclerosis [45–47], promotion of cardiac remodelling [48], alterations in lipid blood
profiles [49] and changes to the morphology of red blood cells [50] (Figure 1). RA-related
inflammation can also be exacerbated by cytomegalovirus infection and is linked to coro-
nary artery damage through the actions of a population of cytotoxic T-cells (reviewed in
detail by Broadley et al. [51]). Autoimmune mechanisms that drive RA progression have
also been linked to abnormal fibrin clot formation and increased CVD risk. However,
the extent to which haemostasis is affected in RA remains unclear (reviewed in detail by
Bezuidenhout et al. [52]).
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Table 2. Studies reporting an association between rheumatoid arthritis disease activity and risk of cardiovascular disease.
Citation Study Type Patients (n) CV Event
Disease Activity Parameters with a
Significant Impact on Risk of CVD
Parameter Impact on Risk





Solomon 2015 [28] RegistryCORRONA US 24,989
Composite of MI,
stroke or CV death CDAI
Risk reduced by 21% per 10 pt
reduction in time-averaged
CDAI




DAS28 (CRP) ≥ 2.6
Worsening of atherosclerosis
only detected in patients with
active disease
Arts 2017 [40] Prospective,inception cohort 1157
Fatal or nonfatal CV
events † DAS28 ≤ 3.2
Reduced risk of CVD
(HR: 0.65; 95% CI: 0.43–0.99) ‡
Mantel 2015 [41] Nested,case–control 138 ACS
Mean DAS28
EULAR ≥ 5.2 §
ESR > 23/> 22 ¶
SJC > 6/> 4 ¶
OR: 1.32 (95% CI: 1.06–1.64)
OR: 2.59 (95% CI: 1.04–6.43)
OR: 3.01 (95% CI: 1.54–5.88)
OR: 1.32 (95% CI: 1.06–1.64)
Ahlers 2020 [42] Electronic healthrecord analysis 6161 Heart failure CRP OR: 1.29 (95% CI: 1.16–1.44)
Bajraktari 2017 [43] Cross-sectional 179 Hypertension CRP, ESR, anti-CCP,DAS28
Significantly higher values
reported in hypertensive
patients (p < 0.001)
Berendsen 2017 [44] Inception cohort 929 Fatal or nonfatal CVevents ‖ RF positivity HR: 1.52 (95% CI: 1.01–2.30) **
* ACS including MI, stable or unstable angina, revascularisation, CV deaths, cerebrovascular events, peripheral vascular events. † ACS,
stable angina pectoris, cerebral vascular accident, transient ischaemic attack, peripheral artery disease and heart failure. ‡ With DAS28 as a
time-dependent variable and after adjustment for confounders, including demographics and traditional CVD risk factors. § EULAR disease
activity score. ¶ Upper tertiles of the population. ‖ Ischaemic heart disease, nonhaemorrhagic cerebrovascular accident or peripheral artery
disease. ** After adjustment for confounders, including demographics and traditional risk factors. Abbreviations: ACPA, anticitrullinated
protein antibodies; ACS, acute coronary syndrome; anti-CCP, anticyclic citrullinated peptide antibodies; CDAI, clinical disease activity
index; CI, confidence interval; CORRONA, Consortium of Rheumatology Researchers of North America; CRP, C-reactive protein; CV,
cardiovascular; CVD, cardiovascular disease; DAS28, Disease Activity Score, including 28 joints; ESR, erythrocyte sedimentation rate;
EULAR, European League Against Rheumatism; HR, hazard ratio; MI, myocardial infarction; OR, odds ratio; PAR, population attributable
risk; RF, rheumatoid factor; SJC, swollen joint count.
Targeted CVD risk management is an important part of the overall clinical manage-
ment of patients with inflammatory joint disorders, including RA [53]. Guidance based
on expert opinion and scientific evidence was issued by EULAR in 2017 and includes
the importance of optimal control of disease activity, CVD risk assessment every 5 years
and lifestyle recommendations [53]. CVD risk prediction models should incorporate a
multiplication factor of 1.5 for patients with RA (if not already included) and screening
for asymptomatic atherosclerotic plaques by carotid ultrasound should be considered;
however, this has not yet been assessed in a clinical setting [53]. In terms of treatment,
nonsteroidal anti-inflammatory drugs (NSAIDs) should be used with caution in patients
with documented CVD or with CVD risk factors, and the dose of GCs should be kept to a
minimum for prolonged treatments [53]. The guidelines also emphasised the important role
of the rheumatologist in CVD risk management [53]. Fortunately, physicians appear to be
aware of the need to monitor CVD risk in patients with active RA: a study of 14,503 patients
in world-wide data from the SUrvey of cardiovascular disease Risk Factor management in
Rheumatoid Arthritis (SURF-RA) database demonstrated that positivity for rheumatoid
factor and anticitrullinated protein antibodies, longer disease duration and higher disease
activity (measured by Disease Activity Score 28 joint count-C reactive protein (CRP)) was
associated with a higher likelihood of lipid and blood pressure assessments [54].
In order to improve the management of comorbidities in chronic inflammatory
rheumatic diseases in daily practice, an initiative supported by EULAR aimed to stan-
dardise reporting and screening of comorbidities [12]. For CVD, this included the use
of a standardised form for reporting a history of ischaemic CV diseases, risk factors and
CVD-related treatments [12].
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3.4. Effect of RA Treatments on CV Risk
In addition to traditional CV risk factors and inflammatory processes, CVD risk
may also be altered by some of the common medications used for the treatment of RA.
For example, corticosteroids and NSAIDs, particularly COX-2 inhibitors, are generally
associated with an increase in CVD risk in patients with RA (reviewed by Jagpal et al. [55]
and DiMizio et al. [18]). Conversely, nonbiologic DMARDs, such as methotrexate, are
associated with an improved CVD risk [56].
As chronic inflammation is considered to be a modifiable risk factor for the devel-
opment of CVD, targeting systemic inflammation with TNF inhibitors has the potential
to reduce CVD risk in patients with RA [57]. This is supported by a meta-analysis from
2015, which demonstrated that TNF inhibitors and methotrexate significantly reduced
the risk of CV events compared with no treatment; however, treatment with NSAIDs or
corticosteroids led to an increase in risk [58]. Similarly, a large study of patients with
RA recruited to the British Society for Rheumatology Biologics Register for Rheumatoid
Arthritis (BSRBR-RA) demonstrated that treatment with TNF inhibitors significantly re-
duced the risk of MI compared with csDMARDs, although no differences in MI severity or
mortality were observed between treatment groups [59]. The benefits of TNF inhibitors
and other biologics were also demonstrated in a prospective cohort study from Australia,
which concluded that, after adjustment for a number of risk factors, the risk of CV events
was significantly reduced following the use of these agents in patients with RA, psoriatic
arthritis (PsA) or ankylosing spondylitis (AS) [60]. Length of treatment may also have
an impact on CV risk, with a large retrospective insurance claims database study in the
USA reporting a positive correlation between duration of treatment with TNF inhibitors
and reduction in CV risk. This study concluded that cumulative use of 1, 2 or 3 years
of anti-TNF therapy is expected to reduce CV risk by 21%, 38% and 51%, respectively,
compared with non-use [61].
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Consistent with the reduced risk of clinical events, treatment with TNF inhibitors may
also lead to improvements in CV abnormalities detected by imaging. For example, patients
with early RA and no CVD history have been shown to have abnormal vascular stiffness,
evidence of diffuse myocardial fibrosis and reduced left ventricular mass compared with
controls. Treatment with methotrexate and etanercept (either concomitantly or following a
step-up strategy) resulted in significant improvements in vascular stiffness after 1 year [62].
Similarly, patients with RA have been reported to have impaired left ventricle longitudinal
strain, which improved after treatment with TNF inhibitors [63].
The benefits of TNF inhibitors on CVD risk correlate with their impact on RA disease
control, with data from the Swedish biologics register demonstrating that the 1-year risk
of ACS for patients with a good EULAR response was approximately half that of patients
with no EULAR response [64]. Similarly, improvements in the apolipoprotein profile,
a biomarker of CVD risk, were observed in patients with RA who exhibited a good or
moderate EULAR response to etanercept but not in EULAR nonresponders [65]. The
relationship between RA disease control and the impact of TNF inhibitors on CV risk
suggests that these agents may exert their effects through reducing systemic inflammation
rather than by modifying traditional CV risk factors. This is supported by a phase IV,
randomised, double-blind, placebo-controlled study, which demonstrated that etanercept
did not affect levels of traditional metabolic risk factors (including glucose, insulin, lipid
and apolipoprotein parameters) despite reducing RA severity, as indicated by decreases
in CRP [66]. Additional support for this theory includes a molecular profiling study,
which demonstrated that patients with RA at the greatest risk of CVD expressed high
levels of biomolecules, which are known to be mediators of autoimmunity, inflammation
and oxidative damage. Importantly, bDMARDs, such as TNF inhibitors and cluster of
differentiation 20 (CD20) inhibitors, were shown to re-establish normal levels of these
circulating biomolecules and, therefore, reduce CVD risk [67].
The impact of newer classes of therapy on CVD risk is also of considerable interest for
the management of patients with RA. Concerns have previously been raised regarding lipid
elevations associated with the interleukin-6 inhibitor tocilizumab, including significantly
increased levels of total and LDL cholesterol [68–70]. However, this does not appear
to translate to increased clinical risks, with a number of studies showing no significant
differences between TNF inhibitors and tocilizumab in terms of CV risk [71–73]. This
included the ENTRACTE randomised controlled trial (RCT), which demonstrated no
significant differences in the risk of MACE between tocilizumab and etanercept in a large
population of patients with RA and at least one CV risk factor [71]. Conversely, there is some
limited evidence that tocilizumab may offer CV benefits compared with TNF inhibitors,
including improvements in lipoprotein markers [74,75] and a lower risk of MACE [76].
Similarly, a large study utilising data from Taiwan’s National Health Insurance claims
database reported that TNF inhibitor nonresponders who received tocilizumab had a lower
risk of CV events compared with patients who received rituximab [77]. The disconnect
between clinical CVD risk and elevated lipids remains to be fully elucidated but may relate
to protective changes to other surrogates of CV risk following treatment with tocilizumab.
For example, in the MEASURE and ADACTA trials, tocilizumab treatment altered high-
density lipoprotein particles towards an anti-inflammatory composition (reduced serum
amyloid A content) and induced a significant reduction in secretory phospholipase A2-IIA,
lipoprotein(a), fibrinogen and D-dimers [68,70]. Abatacept, which inhibits the activation of
T-cells, has also been associated with modest decreases in the risk of CV events compared
with TNF inhibitors [78,79] and rituximab [77].
Janus kinase (JAK) inhibitors and, in particular, tofacitinib, have been associated
with an increased risk of venous thromboembolisms (VTEs) in postmarketing surveillance
studies [80,81]. However, it should be noted that this increased risk was only observed
when tofacitinib was used at a dose of 10 mg twice a day, which is higher than the dose
approved for RA in most countries [82,83]. Moreover, a recent meta-analysis of 26 RCTs,
comprising 11,799 patients, indicated that treatment with JAK inhibitors as a class or as
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individual therapies did not affect the risk of VTEs, CV events or MACE in patients with
RA, at least in the short term [84].
4. Infections in Patients with RA
4.1. Prevalence of Infections in Patients with RA
The risk of infections and serious infections (SI) has long been known to be increased in
patients with RA [85,86]. Historically, a longitudinal, retrospective cohort study of US-based
patients with RA and a disease onset between 1955 and 1994 found the rate of infections
requiring hospitalisation among patients with RA was almost twice that of the age- and sex-
matched patients without RA [85]. More recently, a longitudinal, prospective, real-world
study of patients included in the FORWARD database (the largest patient-reported research
data bank for rheumatic disorders in the US [87]) from 2001 to 2016 reported that the risk
of SI and joint infections was 70% higher in patients with RA (n = 20,361) compared with a
matched cohort of patients with noninflammatory rheumatic and musculoskeletal diseases
(n = 6176; hazard ratio (HR): 1.7; 95% confidence interval (CI): 1.5–1.8) [88]. Subsequent
data from the FORWARD database demonstrated that 5.9% of patients with RA treated
with TNF inhibitors, non-TNF inhibitors, bDMARDs (abatacept, rituximab, tocilizumab
and anakinra) or csDMARDs (n = 11,623) experienced an SI during 27,552 patient-years
of follow-up [89]. Studies from other parts of the world reinforce the association between
RA and the increased burden of infection, with studies from the UK and India reporting
that between 3% and 8% of patients with RA experience infections (Table 3) [90,91]. A
diagnosis of RA may also increase infection risk in a surgical setting, with a retrospective,
US-based case–control study (n = 2212) reporting that RA was associated with a 47%
increased risk of postoperative infection following total joint arthroplasty vs. patients
with osteoarthritis (odds ratio (OR): 1.47; p = 0.031) [92]. Despite the wealth of evidence
supporting the increased susceptibility of patients with RA, infections are suboptimally
prevented, screened for and managed [12].
Table 3. Prevalence of infections in patients with rheumatoid arthritis.
Citation Country Study Type Patients (n) Infection Event Prevalence, n (%) *
Doran 2002 [85] USA Retrospective, cohort 609 IRH 290 (47.6)
Mehta 2019 [88] USA Prospective, cohort 20,361 SI † 1600 (7.9)
Ozen 2019 [89] USA Prospective, cohort 11,623 SI 694 (5.9)
Chandrashekara
2019 [90] India Cross-sectional 2081
Non-tubercular
infection 54 (2.9)
Subesinghe 2016 [91] UK Cross-sectional 929 SI ‡ 72 (7.8)
Salt 2017 [92] USA Retrospective,case–control 55,861
Postoperative joint
infections § 1127 (2.0)
Hashimoto 2017 [93] Japan Retrospective,single-centre 2688 IRH
¶ 274 (10.2)
Rutherford 2018 [94] UK Prospective, cohort,registry: BSRBR-RA 19,282
‖ SI ** 5.51/100patient-years
Richter 2016 [95] Germany Observational, cohort,registry: RABBIT 12,097 SI
†† 947 (7.8)
* Unless otherwise stated. † SI including opportunistic and herpes zoster. ‡ At least one admission to secondary care with an infection
in the preceding year. § In patients with RA or osteoarthritis following total joint arthroplasty. ¶ Including pneumocystis pneumonia. ‖
Patients with RA starting a new biologic. ** Defined as an infection resulting in death, hospitalisation or requiring intravenous antimicrobial
therapy. †† According to International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human
Use definition. Abbreviations: BSRBR-RA, British Society for Rheumatology Biologics Register for Rheumatoid Arthritis; IRH, infection
requiring hospitalisation; RA, rheumatoid arthritis; RABBIT, rheumatoid arthritis: observation of biologic therapy; SI, serious infection.
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Patients with RA are particularly susceptible to bacterial infections (vs. viral or fun-
gal) [88], and those most frequently reported include respiratory infections [88,93], urinary
tract infections (UTI) [93], mycobacterium tuberculosis infection (TB) [96] and sepsis [88]. In-
terestingly, patients with autoimmune inflammatory rheumatic diseases are at an increased
risk of contracting a number of vaccine-preventable infections (influenza, pneumococcal,
disease, herpes zoster (HZ) and human papillomavirus) [97]. Given this, vaccinations
are strongly recommended for this patient population; however, vaccination uptake is
low [91,98]. For instance, a UK-based, real-world study of patients with RA demonstrated
that over 85% of patients were vaccinated against influenza, but only 44% were vaccinated
against pneumococcus [91]. To increase vaccination uptake, the authors advised that col-
laborative approaches between primary and secondary care are required and stressed the
need to overcome potential negative perceptions related to vaccine safety [91].
Preliminary data on COVID-19 in patients with RA have been emerging throughout
2020, and although data are limited at the time of writing in December 2020, most data
indicate that patients with RA are not at an increased risk of contracting COVID-19 com-
pared with the general population [99,100]. A systematic review of eight observational
cohort studies, comprising 6095 patients with rheumatic disease, indicated that patients
were not particularly susceptible to COVID-19. The majority of those infected experienced
a mild clinical course, and there was a low level of fatalities [100]. Two survey studies of
patients with rheumatological diseases also demonstrated that the incidence of COVID-19
and associated symptoms were consistent with the general population [101,102], although,
in a study from the Global Rheumatology Alliance registry, patients with rheumatic dis-
ease (n = 600) and comorbidities, such as hypertension, CVD and diabetes, had higher
odds of hospitalisation due to COVID-19 [103]. Discordantly, a large meta-analysis of 62
observational studies (n = 319,025) from Akiyama et al. demonstrated that patients with
autoimmune disease had a higher prevalence of COVID-19 compared with the general
population [104]. Akiyama et al. also evaluated the results from six case–control studies
that demonstrated that the risk of COVID-19 in patients with RA was significantly higher
than in the control groups (OR: 1.6; 95% CI: 1.1–2.3; p = 0.008) [104]. When interpreting
results, it is important to consider that observational data may underestimate infection risk,
as patients will often be aware of the risks inherent to their disease and may have adapted
their lifestyle to reduce the probability of contracting COVID-19 [105].
4.2. Impact of Infections in Patients with RA
The presence of autoimmune diseases, including RA, appears to increase SI-related
morbidity and mortality; however, data are limited [106,107]. A study from the German
Rheumatoid Arthritis: Observation of Biologic Therapy (RABBIT) biologics register demon-
strated that SI escalated to sepsis or preceded the patient’s death for one in five patients
with RA [95]. A recent study from Germany also reported that mortality due to sepsis in
patients admitted to intensive care was higher in patients with RA compared with age-
and sex-matched controls (p = 0.0016) [106]. Additionally, a study in Brazil showed that
patients with RA and a primary dengue infection had higher rates of hospitalisation and
death compared with patients with RA without dengue infection [108]. Conversely, in a
population-based cohort study in Denmark of patients hospitalised for pneumonia, the
overall 30-day or 90-day mortality rates were not higher for patients with RA compared
with patients without RA [107]. The association between SI and RA disease outcome is
unclear. In a retrospective analysis of 370 patients with RA, multiple SIs that required
hospitalisation were associated with an advanced physical disability and radiological joint
destruction [109]. The results highlight that the influence of RA on SI outcomes, and the
influence of SI on RA outcomes, is complex and warrants further investigation.
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4.3. Risk Factors for Infections in Patients with RA
The increased infection risk in patients with RA has been attributed to the impact
of immunocompromising comorbid conditions, the underlying immune dysregulation
associated with the disease itself and the sequelae of immunosuppressive therapy [86,89].
However, it is difficult to quantify the specific contribution of each of these factors.
4.3.1. Comorbidities as a Risk Factor for Infection in Patients with RA
A number of patient demographics and comorbidities have been shown to be predic-
tive of the observed increased risk of infection in patients with RA [86]. Factors associated
with an increased infection risk include male sex [92,93,96], older age [90,93,95,96,110,111],
longer RA disease duration [90,93], a history of SIs [88], lower education [90], family in-
come [90], rural residency [88], geographical location [111], poor nutritional status [112] and
higher BMI [111]/obesity [92]. Significantly increased infection risks have been described
for patients with comorbid conditions including renal dysfunction [93,95,113], pulmonary
disease [89], underlying lung disease [93,112] and diabetes [88,92,111]. The number of
comorbidities has been observed to correlate with an increased risk of infection [88,89].
4.3.2. Disease Activity as a Risk Factor for Infection in Patients with RA
There is evidence suggesting that the inflammatory processes underlying RA may
also drive the development of infections. This is supported by the numerous studies
demonstrating the association of active RA with an increased risk of infection. For instance,
in a retrospective analysis of patients enrolled in the US-based CORRONA registry, the
adjusted risk of SI was 69% higher in patients with sustained low disease activity compared
with those in sustained remission (adjusted incidence rate (IR) ratios: 1.7; 95% CI: 1.3–2.2).
In patients with moderate-to-high disease activity, the risk of SI was more than double that
observed for patients in sustained remission (IR/100 patient-years: 2.5; 95% CI: 2.2–2.8
vs. IR/100 patient-years: 1.0; 95% CI: 0.9–1.3) [114]. In addition, the aforementioned
population-based cohort study in Denmark of patients hospitalised for pneumonia demon-
strated that high RA disease activity prior to hospitalisation was associated with a five-fold
increased risk of 90-day mortality compared with patients with low RA activity, although
overall mortality rates were not higher for patients with RA vs. patients without RA (19.9%
and 18.9%, respectively) [107]. A study of the FORWARD database reported that compared
with patients with noninflammatory rheumatic and musculoskeletal diseases, patients with
RA with low disease activity, or in remission, had a similar SI risk; however, patients with
moderate and high RA disease activity had a significantly increased SI risk [88]. Authors of
these studies discussed the clinical relevance of their results and suggested that for patients
with high RA disease activity, the treatment goal should be to obtain low-grade disease
activity or remission as this may result in improved outcomes for patients with SI [88,107].
Accortt et al., authors of the study of the CORRONA registry, even suggested that their
results may incentivise patients and health care providers to strive for remission rather
than low disease activity [114]. In contradiction, however, Mehta et al. cautioned that while
low disease activity/remission is an attractive target, clinicians should weigh the potential
SI risk associated with aggressive treatment strategies in patients with RA while targeting
and sustaining remission or low disease activity [88].
4.3.3. Treatment Regimens and the Risk of Infection in Patients with RA
Regimens used frequently in the treatment of RA, including GCs and DMARDs, have
been associated with an increased risk of infection or the reactivation of latent infections
(Table 4).
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Table 4. Studies investigating associations between rheumatoid arthritis treatment regimens and the risk of infection.
Citation Study Type Patients (n) * Infection Event
Treatments with an Impact on the Risk of Infection





GC OR (95% CI): 3.0 (2.1–4.4); p < 0.0001(2 mg/day)
bDMARD OR (95% CI): 1.4 (1.0–2.0); p = 0.033
MTX OR (95% CI): 0.7 (0.6–1.0); p = 0.034
Mehta 2019 [88] Prospective,cohort 20,361 SI GCs
HR (95% CI) for patients with RA vs.
NIRMD:
• Excluding GCs: 1.7 (1.5–1.9)










OR (95% CI) for sepsis:
• GC 5 to <10 mg/day vs. ref †:
1.3 (0.8–1.9)
• GC ≥ 10 mg/day vs. ref †: 1.7
(1.0–2.9)
OR (95% CI) for death:
• GC 5 to <10 mg/day vs. ref †:
0.9 (0.5–1.8)
• GC ≥ 10 mg/day vs. ref †: 2.4
(1.0–5.6)
TNF inhibitor
OR (95% CI) sepsis vs. ref ‡: 0.6
(0.4–1.0)
OR (95% CI) death vs. ref ‡: 0.5
(0.2–1.0)
Other bDMARD
OR (95% CI) sepsis vs. ref ‡: 0.5
(0.3–0.8)
OR (95% CI) death vs. ref ‡: 0.2
(0.1–0.5)
Ozen 2019 [89] Prospective,
cohort
11,623 SI
TNFis Adjusted HR (95% CI) vs. ref
‡: 1.3
(1.1–1.7)
Non-TNFi bDMARD Adjusted HR (95% CI) vs. ref
‡: 1.5
(1.0–2.2)
Strand 2015 [115] Meta-analysis 66 RCTs;22 LTS SI
Tofacitinib 5 mg BID



























(n = 2236) ¶
SI TNFis vs. placebo
Fixed-effects model (OR: 1.4; 95% CI:
1.2–1.7)
Random-effects model (OR: 1.3; 95%
CI: 1.0–1.6)
* Unless otherwise stated. † Reference; GC (<5 mg/day). ‡ Reference; csDMARD. § DMARD-inadequate responder patients only. ¶ With RA,
PsA or AS. Abbreviations: AS, ankylosing spondylitis; bDMARD, biologic DMARD; BID, twice daily; CI, confidence interval; csDMARD,
conventional synthetic DMARD; DMARD, disease-modifying antirheumatic drug; GCs, glucocorticoids; HR, hazard ratio; IRH, infection
requiring hospitalisation; LTS, long-term extension study; MTX, methotrexate; NIRMD, noninflammatory rheumatic and musculoskeletal
diseases; OLE, open-label extension study; OR, odds ratio; PsA, psoriatic arthritis; RA, rheumatoid arthritis; RABBIT, Rheumatoid
Arthritis: Observation of Biologic Therapy; RCT, randomised controlled trial; Ref, reference; SI, serious infection; TNFi, tumour necrosis
factor-α inhibitor.
GCs Increase the Risk of Infection in Patients with RA
GCs are effective and widely used in RA, although the benefit-to-risk ratio of this
treatment remains precarious [118]. The role of GCs in increasing patient susceptibility to
SIs and the associated mortality is supported by numerous studies [88,93,95]. For example,
in a study of the FORWARD database, the current use of GCs was the strongest predictor
of SI. Additionally, when the HR was adjusted to account for GC use, the excess risk of SI
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for patients with RA, compared with a matched cohort of patients with noninflammatory
rheumatic and musculoskeletal diseases, was attenuated from 70% to 30% (HR: 1.3; 95%
CI: 1.2–1.5) [88].
csDMARDs and the Risk of Infection in Patients with RA
Evidence suggests that csDMARDs, such as methotrexate, confer no increased risk for
SI or SI-associated mortality in patients with RA [107]. Indeed, the addition of methotrexate
to a bDMARD regimen did not increase the risk of SI compared with bDMARD monother-
apy in a meta-analysis of patients with RA [119]. These conclusions, however, differ from
those from a Japanese cohort study, which identified the use of methotrexate as a risk factor
for Pneumocystis pneumonia, although methotrexate use was negatively associated with
the incidence of all infections [93].
bDMARDs and the Risk of Infection in Patients with RA
The risk of infection is generally increased with bDMARDs compared with csD-
MARDs [89,116]. In a large meta-analysis of 106 trials published between 1992 and 2014,
an increase in the risk of SI was reported for patients treated with standard- or high-dose
bDMARDs compared with csDMARDs; however, no increase in risk was noted for patients
treated with low-dose bDMARDs [116]. Correspondingly, in a 10-year retrospective review
in patients with RA in Western Australia, the mean duration of bDMARD use correlated
with a greater risk of SI (p = 0.04) [110]. These conclusions differ from those reported by
Richter et al. that patients treated with bDMARDs had a significantly lower risk of devel-
oping sepsis (OR: 0.6; 95% CI: 0.4–0.8) and had a significantly lower mortality risk than
those treated with csDMARDs. Richter et al. proposed that successful immunosuppression
may prevent escalation to sepsis but noted that further investigation is required [95].
TNF Inhibitors and the Risk of Infection in Patients with RA
The increased risk of infections is one of the most important considerations when
prescribing TNF inhibitors, although the magnitude of this risk is a topic of debate [120].
Results from a study of the FORWARD database demonstrated that the SI incidence
rate per 1000 patient-years was increased in patients receiving TNF inhibitors (26.9; 95%
CI: 24.5–29.6) or non-TNF-inhibitor bDMARDs (23.3; 95% CI: 19.0–28.5) vs. csDMARDs
(22.4; 95% CI: 19.2–26.1) (Table 4) [89]. A meta-analysis of 71 RCTs and seven open-label
extension studies in patients with RA, PsA and AS in 2014 found significant increases in
the occurrence of any infections, SI and TB associated with TNF inhibitor treatment (20%,
40% and 250%, respectively) [117]. These findings, however, differ from those from the
BSRBR-RA, where it was reported that patients with RA who discontinued TNF inhibitors
60 days after an SI were at higher risk of SI recurrence compared with patients who
remained on TNF inhibitor therapy or switched to a different biologic class [121]. There
are a number of explanations for this discrepant observation; it is possible that there is a
clinical advantage of continuing biologic immunosuppression following an SI, although
the authors advise against inferring a causal link. It could be that these data reflect a
channelling bias whereby the “fittest” patients with the lowest baseline risk of experiencing
recurrent SI were preferentially selected to restart biologics post-SI [121]. Overall, data
suggest that TNF inhibitor use is associated with an increased risk of infection in patients
with RA.
Differences in the infection risk between individual TNF inhibitors is difficult to
determine due to the scarcity of head-to-head RCTs and the difficulties associated with
cross-trial comparisons. Data from a US RA registry study demonstrated that there were
no differences in the risk of SI between certolizumab pegol compared with other TNF
inhibitors (etanercept, adalimumab, golimumab or infliximab) [122]. Contrastingly, a meta-
analysis of 12 observational studies reported a lower incidence of SI in patients receiving
etanercept compared with the TNF inhibitors infliximab or adalimumab (relative risk (RR):
0.6; 95% CI: 0.4–1.0; p = 0.04), although the authors noted that heterogeneity between the
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studies was high and likely due to differences in study designs and clinical features and,
therefore, cautioned against drawing conclusions [120]. Data from a 10-year retrospective
review demonstrated that the lowest rate of SI was observed in those receiving treatment
with adalimumab (5.3/100 person-years) and it was highest with infliximab (34.5/100
person-years) vs. other bDMARDs [110].
Multiple studies have reported no significant differences in the risk of infection be-
tween TNF inhibitors when compared with other biologics and drug classes. For instance,
a study of the BSRBR-RA reported that after adjusting for confounding variables, there
were no differences between a number of different biologics (all biologics, TNF inhibitors,
rituximab and tocilizumab) in the risk of SIs for patients with RA [96]. A study of the
FORWARD database also demonstrated that the risk of SI among patients with RA treated
with TNF inhibitors was not significantly different from that observed with other non-TNF-
inhibitor bDMARDs [89]. However, other studies have reported specific differences. A
study of claims data from US Medicare reported that the risk of serious bacterial infections,
diverticulitis, and skin and soft tissue infections was lower in patients receiving TNF in-
hibitors compared with those receiving tocilizumab; however, no differences in the risk of
SI overall were reported [123]. Discordantly, in Rutherford et al.’s study of the BSRBR-RA,
patients with RA treated with etanercept had a lower risk of SI vs. patients treated with
tocilizumab (HR: 1.2; 95% CI: 1.0–1.5) [94]. It is worth noting that channelling bias can
present a challenge with such trial designs, particularly when some treatments are adminis-
tered in a first-line setting and others are more routinely administered later in the treatment
pathway. However, to account for this, Rutherford et al. excluded biologic-naïve patients
in a sensitivity analysis and the results remained significant. Rutherford et al. also reported
that prior to adjusting for confounding, etanercept had a lower incidence of infection than
rituximab; however, once adjusted, the difference lost significance, suggesting that patient
factors rather than the regimen itself may be responsible for the difference [94]. A separate
study of the BSRBR-RA from the same group found that the incidence of pneumocystis
was significantly lower following treatment with TNF inhibitors vs. rituximab (adjusted
HR: 3.2; 95% CI: 1.4–7.5) [96].
There are also limited data suggesting that patients treated with TNF inhibitors
may have an increased risk of hospitalisation due to infection compared with patients
treated with abatacept. Evidence from a propensity-score-matched study of 11,248 pairs
of patients with RA included in the MarketScan database demonstrated increased rates
of hospitalisation due to infection in patients treated with TNF inhibitors (as a class)
compared with those treated with abatacept (HR: 0.8; 95% CI: 0.6–1.0) [124]. Of note,
hospitalisation rates due to infection continued to be higher when infliximab was compared
with abatacept (HR: 0.6; 95% CI: 0.5–0.9), although no significant differences were reported
when etanercept or adalimumab was compared with abatacept [124]. Conversely, a cohort
study analysing Medicare data reported that patients treated with etanercept, infliximab
or rituximab had a significantly higher 1-year risk of hospitalisation due to infection than
patients treated with abatacept (adjusted HRs: 1.2, 1.4 and 1.4, respectively). In contrast,
no significant differences were reported for adalimumab, certolizumab, golimumab or
tocilizumab when compared with abatacept, after adjusting for potential confounding
factors (adjusted HRs for all: 1.1) [125].
tsDMARDs and the Risk of Infection in Patients with RA
The more recently introduced tsDMARDs, such as JAK inhibitors, have an unclear
association with infection risk. Some studies report that JAK inhibitors have a similar
risk for infections as bDMARDs; for example, the SI rate for tofacitinib in RA clinical
trials was approximately 3 per 100 patient-years [115]. Moreover, in a systematic analysis
of 21 studies of tofacitinib, baricitinib and upadacitinib, the IRs for SI were 2.0 (95% CI:
1.4–2.7), 3.2 (2.1–4.6) and 3.0 (1.0–7.0), respectively [126]. Discordantly, an on-going, open-
label, postmarketing clinical study evaluating the safety of tofacitinib compared with TNF
inhibitors (etanercept or adalimumab) in patients with RA demonstrated that tofacitinib
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was associated with increased mortality, which was partially attributable to the increased
SI risk, vs. TNF inhibitors [81]. Based on this observation, the European Medicines Agency
recommends that patients aged over 65 years should only be treated with tofacitinib when
there is no suitable alternative treatment [82]. It is evident that the general SI risk with JAK
inhibitors is not yet fully understood, and it will be interesting to see what further research
reveals.
A significant association between HZ risk and treatment with JAK inhibitors has been
reported [126], a finding supported by a study of the German registry, RABBIT, which
also demonstrated an increased risk for HZ following tsDMARD treatment (HR: 3.6; 95%
CI: 2.3–5.4) [127]. These results also agree with findings from a pooled analysis with a
total of 8.5 years of tofacitinib exposure, where SIs were observed in 8.5% of patients at a
rate of 2.7 per 100 patient-years, which did not increase during the follow-up [111]. The
most common types of infection from the pooled analysis were pneumonia, HZ, UTI and
cellulitis; HZ occurred at a rate of 3.9 (95% CI: 3.6–4.2) per 100 patient-years [111]. These
results support the HZ vaccination of patients with RA, particularly if patients are to
receive JAK inhibitors.
RA Treatment Regimens and the Risk of Reactivating Latent Infections
TNF inhibitors have been associated with an increased risk of reactivating latent
infections. In a meta-analysis of randomised studies, exposure to TNF inhibitors was
associated with a three-fold increase in the risk of TB reactivation compared with placebo
or no treatment (fixed-effects model, OR: 3.5, 95% CI: 1.6–7.9; random-effects model, OR:
3.3, 95% CI: 1.5–7.3) [117]. The risk of TB infection and reactivation also appears lower in
etanercept-treated patients compared with those treated with infliximab or adalimumab, as
observed in several studies [96,120,128]. In patients with risk factors for TB, etanercept may,
therefore, be the most suitable TNF inhibitor of choice. Moreover, the incidence of TB was
significantly higher among those treated with TNF inhibitors compared with rituximab [96].
TNF inhibitors are also reported to increase the likelihood of hepatitis consequent to
hepatitis B virus (HBV) reactivation; however, data on the specific increased risks vary
between TNF inhibitors, from 12.5% to 62.5% [129–131]. The potential for reactivation of
HBV in patients treated with TNF inhibitors has been compared with non-TNF-inhibitor
bDMARD therapy in a retrospective cohort study, which demonstrated no reactivation of
HBV in the group receiving TNF inhibitors, compared with two cases in the group that
received bDMARDs; however, this difference was not significant (p = 0.226) [132].
Other regimens used frequently in the treatment of RA have also been associated with
an increased risk of reactivating latent infections, including HZ [133,134] and HBV [135].
Patients receiving GC and/or csDMARD therapy have an established increased risk of
HBV reactivation, and bDMARD therapy is also emerging as a potential driver for hepatitis
reactivation [135]. This is evident by the boxed warning regarding HBV reactivation that
has been added to the prescribing information for the bDMARD rituximab [136]. Indeed,
the Centers for Disease Control and Prevention Guidelines recommend screening for HBV
prior to initiating immunosuppressive therapies [137]. Moreover, the EULAR and Italian
consensus guidelines also state that patients with rheumatic diseases, classified as “at risk”,
should be vaccinated against HBV [98,138].
The impact of HBV infection on clinical response to bDMARDs is less well docu-
mented. A retrospective analysis of occult HBV infection and the impact it has on drug
survival in patients with RA was conducted using the Biologic Apulian Registry [139]. This
study revealed that patients with occult HBV (n = 110) were significantly more likely to
receive tocilizumab or abatacept as their first DMARD compared with those who were
occult-HBV-negative (n = 376). Patients with occult HBV had significantly lower drug sur-
vival rates compared with patients without occult HBV. Consequently, patients with occult
HBV had higher levels of discontinuation due to drug ineffectiveness (occult-HBV-positive,
66.4% vs. occult-HBV-negative, 75.3%; long rank: 7.9; p = 0.005) [139]. This finding further
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emphasises the importance of screening and monitoring patients for certain infections prior
to initiating, and during, treatment with immunosuppressive therapy.
The Impact of RA Treatment Regimens on the Severity of COVID-19 Infection
Studies on the impact of RA therapies on the severity of COVID-19 infection are lim-
ited, and professional organisations, such as EULAR, have described themselves as “flying
blind” due to the novelty of the pandemic and the lack of sound evidence [140]. Thus far,
data, however limited, indicate that GC usage may increase the risk of hospitalisation in in-
fected patients with rheumatic disease when compared with other treatment regimens [141].
For example, a prospective study on the impact of COVID-19 in patients with inflammatory
arthritis (n = 103) in the US demonstrated that those receiving GCs had a higher risk of
being admitted for COVID-19 infection (adjusted OR: 21.1; 95% CI: 4.1–109.0; p < 0.001),
whereas patients on anticytokine bDMARDs did not [142]. Moreover, in the aforemen-
tioned publication from the Global Rheumatology Alliance Global Registry, a prednisone
dose ≥10 mg/day was associated with a higher risk of hospitalisation with COVID-19 (OR:
2.1; 95% CI: 1.1–4.0) in patients with rheumatoid disease [103]. In the same study, the use of
csDMARDs as a monotherapy or in combination with biologics or JAK inhibitors was not
associated with an increased risk of hospitalisation (OR: 1.2, 95% CI: 0.7–2.2, and OR: 0.7,
95% CI: 0.4–1.5, respectively) [103]. Interestingly, TNF inhibitor use was associated with a
reduced risk of hospitalisation (OR: 0.4; 95% CI: 0.2–0.8) [103]. Reassuringly, data from two
small preliminary studies also indicate that patients receiving b/tsDMARD therapy do not
appear to be at an increased risk of COVID-19-associated complications compared with the
general population [100,143]. However, these studies are based on limited sample sizes.
Results from the large meta-analysis by Akiyama et al. demonstrated that patients with au-
toimmune disease treated with GCs, csDMARDs or b/tsDMARD–csDMARD combination
therapy had a 2–3 times higher rate of hospitalisation and death due to COVID-19 when
compared with those treated with b/tsDMARD monotherapy [104]. Importantly, patients
receiving TNF inhibitor monotherapy had a lower rate of hospitalisation and mortality
compared with those receiving non-TNF-inhibitor monotherapy [104]. The association
between rituximab treatment and COVID-19 risk is currently unknown; however, the
incidence of severe COVID-19 infection was increased in patients treated with rituximab
compared with patients treated with infliximab in a small single-centre study [144]. This
finding was supported by two separate, small, single-centre studies that reported a higher
risk of hospitalisation in patients treated with rituximab but not in those treated with
TNF inhibitors or other bDMARDs [145,146]. Based on the current evidence, patients
should be able to continue their current regimens, particularly if patients are receiving
TNF inhibitor monotherapy. Preliminary guidance from EULAR advises that patients who
do not have suspected or confirmed COVID-19 should continue their treatment regimen
unchanged [140].
5. Lymphoma and NMSC in RA
5.1. Prevalence of Lymphoma in Patients with RA
Patients with RA have an increased risk of developing lymphoma, with a meta-
analysis of eight epidemiological studies reporting that the risk is more than doubled
compared with the general population (pooled standardised incidence ratio: 2.5) [147]. The
risks of developing non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) are
both increased in patients with RA [147,148], with diffuse large B-cell lymphoma (DLBCL)
the most frequently encountered lymphoma subtype [148,149]. A relatively recent study
from Hellgren et al. in 2017 confirmed that the lymphoma risk in recently diagnosed
RA patients has not decreased compared with that reported in historical cohorts, despite
improvements in the management and treatment of RA [150]. This Swedish cohort study
of 12,656 incident cases of RA reported a 60% increase in the risk of lymphoma compared
with the population norm (HR: 1.6; 95% CI: 1.2–2.1). Because of this increased risk, it is
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recommended in a EULAR initiative that malignancies, such as lymphoma, are carefully
assessed and managed in patients with chronic inflammatory rheumatic diseases [12].
5.2. Impact of RA on Outcomes in Patients with Lymphoma
A small number of studies have suggested that the presence of autoimmune diseases,
including RA, may be an adverse prognostic factor among patients with lymphoma. For
instance, a large cancer registry study in Sweden demonstrated that the risk of death due to
cancer was significantly higher in patients with a previous hospitalisation for RA (n = 6309)
than in patients without RA (n = 1,404,854) [151]. This was true for all cancers (HR for
cause-specific survival: 1.3; 95% CI: 1.3–1.3) but especially for NHL (HR: 1.4; 95% CI: 1.2–
1.7) and SCC (HR: 1.9; 95% CI: 1.0–3.5). A separate Swedish cohort study reported that a
self-reported history of autoimmune disease (RA, systemic lupus erythematosus, Sjögren’s
syndrome or coeliac disease; n = 97) was associated with an increased risk of all-cause death
(HR: 1.4; 95% CI: 1.0–1.8; p = 0.03) and a trend for an increased risk of lymphoma-related
death (HR: 1.3; 95% CI: 1.0–1.8; p = 0.08) in patients with NHL (n = 1523) [152]. More
recently, a prospective cohort study by Kleinstern et al. demonstrated that a history of
autoimmune conditions primarily mediated by B-cell responses was associated with worse
event-free survival in patients with mantle cell lymphoma (HR: 2.2; 95% CI: 1.2–4.3; n = 193)
or HL (HR: 2.6; 95% CI: 1.0–6.6; n = 297) and that this was largely driven by RA [153]. A
hospital-based case–control study, also by Kleinstern et al., showed that in patients with
B-cell NHL (n = 435), time to relapse was significantly shorter for patients with a history
of autoimmune disease compared with control patients (HR: 1.7; 95% CI: 1.0–2.8) [154].
In patients with DLBCL (the most commonly observed B-cell NHL subtype), a history of
B-cell-mediated autoimmune disease was associated with both shorter relapse-free survival
(HR: 8.3; 95% CI: 3.0–23.1) and overall survival (HR: 3.8; 95% CI: 1.2–12.3) compared with
controls [154]. In contrast, a smaller US study reported that NHL patients with RA (n = 65)
had similar overall survival rates, but a significantly lower risk of lymphoma progression
or relapse (HR: 0.4; 95% CI: 0.3–0.7) or death related to lymphoma or its treatment (HR:
0.6; 0.4–1.0), compared with NHL patients without RA (n = 1530) [155]. Similar results
were reported when the analysis was limited to patients with DLBCL. Of note, NHL
patients with RA were found to be twice as likely as patients without RA to die from causes
unrelated to lymphoma or its treatment (HR: 2.2; 95% CI: 1.3–3.5) [155]. It is evident from
the results of these studies that the association between RA and lymphoma outcomes is
complex and requires further investigation.
5.3. Risk Factors for Development of Lymphoma in Patients with RA (Including Effect of
TNF Inhibitors)
Factors that contribute to the development of lymphoma in patients with RA remain
to be fully elucidated; however, there is strong evidence that the inflammatory processes
underlying RA may also drive the development of lymphoma. This is supported by a
number of studies, which were performed prior to the time period covered by our literature
review, showing that the risk of lymphoma is higher in patients with more severe disease
activity. For example, a nested case–control study of Swedish patients with RA prior to
the introduction of biologics (1965–1983, n = 11 683) reported a strong association between
high inflammatory disease activity and the risk of developing lymphoma (OR vs. low
activity: 25.8; 95% CI: 3.1–213.0) [156]. Subsequently, in a matched case–control study
of 378 patients with RA and lymphoma (1964–1995), the same group demonstrated that
the risk of lymphoma was increased 70-fold in the subset of RA patients with the highest
inflammatory disease activity (unadjusted OR vs. low activity: 71.3; 95% CI: 24.1–211.4),
but by only eight-fold in patients with intermediate disease activity (unadjusted OR: 7.7;
95% CI: 4.8–12.3) [157]. A similar study of 1767 consecutive patients with RA with 15,832
patient-years of follow-up demonstrated that persistent inflammatory activity (defined as
an elevated erythrocyte sedimentation rate) was associated with a nine-fold increase in the
risk of NHL [158].
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There is great interest in whether treatment with TNF inhibitors further increases
the risk of lymphoma in patients with RA. Following the issuing of a US Food and Drug
Administration (FDA) black box warning in 2009 for the use of TNF inhibitors and the
risk of developing NHL (based on limited data), a nested case–control study within a
retrospective cohort of adult patients with rheumatologic conditions (RA, PsA or AS),
drawn from a US commercial health insurance database, was undertaken to fully assess
any potential risk [159]. This analysis revealed that compared with matched controls
(n = 984), patients with NHL (n = 101) had greater TNF inhibitor use (33% vs. 20%), with
any use of a TNF inhibitor associated with an almost two-fold increased risk of NHL (OR:
1.9; 95% CI: 1.2–3.2). When analysed by drug, etanercept was associated with an increased
NHL risk (OR: 2.7; 95% CI: 1.4–5.3), but no significant associations were reported for
other TNF inhibitors. The findings from this study also suggested an increasing risk with
increasing duration of therapy (p-value for trend: 0.05). Considering these observations,
the authors concluded that the FDA black box warning was warranted and that continued
surveillance for this potential adverse outcome is required [159]. In addition, a pooled
analysis of 11,317 patients with autoimmune diseases treated with the TNF inhibitor
certolizumab pegol in clinical trials demonstrated that for patients with RA, lymphatic and
haematopoietic cancer incidence (principally lymphoma) was increased compared with
the age- and gender-matched GLOBOCAN/SEER general population (standardised IR:
2.1; 95% CI 1.2–3.6) [160]. These results, however, differ from those from the BSRBR-RA.
After adjusting for differences in baseline patient characteristics, a prospective cohort
analysis of the BSRBR-RA database found no difference in the risk of lymphoma for RA
patients receiving TNF inhibitors (n = 11,931) compared with those who were biologic-naïve
(n = 3367) (HR: 1.0; 95% CI: 0.6–1.8), suggesting that TNF inhibition does not influence
the risk of lymphoma over the background risk in patients with RA [161]. These results
concur with the findings of a collaborative European registry study that examined the
increased risk of both HL and NHL in patients with RA [149]. After examining the
potential role of a variety of treatments, including bDMARDs and TNF inhibitors, the
authors concluded that the risk of lymphoma in RA may be related to the disease itself
rather than the chosen treatment approach, with use of TNF inhibitors having no apparent
effect on the subtypes of lymphoma observed [149]. A study of 12,656 cases of incident
RA from a Swedish registry also reported no impact of TNF inhibitors on the risk of
lymphoma [150]. Moreover, a more recent study by the same Swedish group suggested no
increase in lymphoma risk for patients with RA starting a first bDMARD (TNF inhibitor or
non-TNF-inhibitor drug; n = 16,392) compared with bDMARD-naïve patients (n = 55,253)
and no signals of different risk with any particular TNF inhibitor agent [162]. These
accumulating data from large national registries, therefore, call into question the earlier
data suggesting a link between TNF inhibitor use and the development of lymphoma.
Notably, a recent overview of systematic reviews and meta-analyses of malignancy risk
with TNF inhibitors noted no increase in lymphoma risk in patients with RA [163]. With
respect to csDMARDs, there is currently no compelling evidence to suggest an association
between methotrexate use and lymphoma risk in patients with RA, as reviewed in Klein
et al. [148]. The aforementioned study of 12,656 cases of incident RA from a Swedish
registry reported no impact of methotrexate on the risk of lymphoma [150]. However, a
large historical case-control study of patients with RA from Canadian databases (n = 23,810)
noted that the adjusted RR for lymphoma was slightly increased (1.2; 95% CI: 1.0–1.6)
following methotrexate therapy [164].
5.4. Prevalence of NMSC in Patients with RA
Studies in patients with RA have reported increases in the risk of NMSC compared
with the general population [165–167], including in those naïve to biologics [166,167]. These
findings are supported by data from a large population-based cohort study in Sweden,
which showed a small to moderately increased risk of BCC for biologic-naïve patients with
RA (n = 46,409) compared with the general population (HR: 1.2; 95% CI: 1.1–1.4) [168]. The
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same study reported that the risk of SCC was nearly doubled in biologic-naïve patients
compared with the general population (HR: 1.9; 95% CI: 1.7–2.0) [168].
5.5. Risk Factors for NMSC in Patients with RA
Studies have suggested a link between treatment, especially methotrexate and TNF
inhibitors, and the risk of developing NMSC in patients with RA. A retrospective analysis
of data from a mixed population of patients with RA or PsA in Tasmania, Australia
(n = 405), identified an increased risk of both BCC and SCC among patients exposed to
methotrexate [169]. Methotrexate use was associated with a standardised IR of 4.6 (95%
CI: 0.7–33.2) for at least one confirmed NMSC case compared with no methotrexate usage.
An increased risk of NMSC was also apparent among patients exposed to combinations
of corticosteroids (RR: 2.5; 95% CI: 1.2–5.1) or D-penicillamine (RR: 3.5; 95% CI: 1.3–4.6),
both with concomitant methotrexate. While not undertaken in RA patients, prespecified
secondary analyses of the large Cardiovascular Inflammation Reduction Trial in 4786 adults
with CVD and diabetes or metabolic syndrome reported an association between low-dose
methotrexate use and skin cancers (HR: 2.1; 95% CI: 1.3–3.3), especially SCC (HR: 3.3; 95%
CI: 1.6–6.7) [170]. These findings, which indicate a link between methotrexate use and the
development of skin cancers in patients without inflammatory rheumatic conditions, could,
in part, explain the higher rate of NMSC in patients with RA (most of whom have received
methotrexate) compared with the general population [171].
The risk of NMSC in patients with RA receiving TNF inhibitors has been examined
in multiple studies. In a recent systematic review and meta-analysis of six studies in
123,023 patients, an increased risk of NMSC (RR: 1.3; 95% CI: 1.2–1.4; p = 0.056), especially
SCC (RR: 1.3; 95% CI: 1.1–1.5; p = 0.854) but not BCC (RR: 1.1; 95% CI: 1.0–1.3; p = 0.555),
was observed in patients with RA treated with TNF inhibitors compared with patients
not receiving TNF inhibitors [172]. A meta-analysis from Askling et al., comprising 74
RCTs using adalimumab, etanercept or infliximab (n = 15,418), also demonstrated that the
overall risk of NMSC was doubled following TNF inhibitor use compared with comparator
arms (HR: 2.0; 95% CI: 1.1–4.0) [173]. The incidence of NMSC was also evaluated in a
national cohort of US veterans with RA receiving TNF inhibitors and non-bDMARDs
(n = 20,648) [174]. Patients receiving TNF inhibitors had a higher risk of developing NMSC
vs. patients receiving non-bDMARDs (HR: 1.4; 95% CI: 1.2–1.6) [174]. These findings
suggest an increase in NMSC risk, particularly SCC risk, with TNF inhibitor therapy;
further studies are required to explore the factors that underlie this increase.
6. Conclusions
Much of the literature implicates dysregulated systemic inflammatory responses in
the pathogenesis of comorbidities associated with RA. While the contemporary clinical
treatment goal is to achieve remission, the ideal immunological treatment goal is to achieve
an immune homeostasis, such that the immune system can respond dynamically and ap-
propriately to the environment. In keeping with this concept, the literature reviewed here
emphasises the importance of optimal inflammation control, with a view to minimising
or preventing the key complications of RA. However, immunosuppression, and a corre-
sponding increase in infection risk, is a danger of over-treatment with TNF inhibitors and
other targeted therapies. Similarly, the TNF blockade may be associated with an increased
risk of NMSC, and, therefore, regular skin examination is desirable for patients with RA
treated with TNF inhibitors. Conversely, TNF inhibitors and other biologics offer benefits
that extend beyond amelioration of articular manifestations of RA and, in particular, to
improvements in CV health. With the emergence of biosimilars to several TNF inhibitors,
access to these agents is expected to rapidly increase in the coming years, potentially lead-
ing to initiation of treatments at an earlier disease stage. An anticipated advantage of earlier
access to treatment, and a correspondingly improved control of systemic inflammation
over time, is the prevention of CV complications that may otherwise be incurred due
to sustained systemic inflammatory responses. Broader and earlier treatment with TNF
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inhibitors may also reduce the occurrence of other comorbidities as well as joint symptoms.
However, it is important to mitigate the risk of overtreatment and immunosuppression,
and this must be considered in the context of the responsible management of RA. For those
patients achieving prolonged and sustained disease remission, step-down approaches may
be appropriate, with a subsequent careful review of progress. A shared decision-making
approach will be critical and should take into account the unique clinical situation of any
given patient and the benefit–risk profile that they consider to be appropriate.
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